The Therapeutic Monoclonal Antibody Product Market

The MAb market has continued to grow for the past several decades, with MAb products now the dominant product class within the biopharmaceutical market. Can we expect that growth to continue? See what the future holds for this market, based on findings from BDO’s bioTRAK database.
 

Read the Full Article

Related Resources

Article

Benefits of Using Real-Time In-Process Data in Mammalian Cell Culture

April 5, 2024
Article

Benefits of Using Real-Time In-Process Data in Mammalian Cell Culture

April 5, 2024

Learn how real-time monitoring of key data in mammalian cell-based protein therapeutics production can refine your control strategy and prevent expensive setbacks.

Read More

Article

USTR Seeking Comments on Supply Chain Resilience

April 3, 2024
Article

USTR Seeking Comments on Supply Chain Resilience

April 3, 2024

On March 7, 2024, the Office of the United States Trade Representative (USTR) announced a notice in the Federal Register seeking comments to “inform the development of trade and investment policy initiatives that promote supply chain resilience.” A public hearing will follow.

Read More

Article

District Court Allows Whistleblower’s Customs Fraud Suit to Proceed

February 23, 2024
Article

District Court Allows Whistleblower’s Customs Fraud Suit to Proceed

February 23, 2024

The U.S. District Court for the Southern District of New York on January 26, 2024, declined to dismiss a False Claims Act (FCA) civil lawsuit filed by a whistleblower, which alleges that their employer misclassified imported footwear to avoid customs duties and that they were constructively discharged in retaliation for objecting to the employer’s illegal practices.

Read More

Article

Top 6 Life Sciences Trends for 2024

February 7, 2024
Article

Top 6 Life Sciences Trends for 2024

February 7, 2024

In the past year, the life sciences industry has struggled with high interest rates and a tight cash environment. The high-risk characteristics of the industry, combined with the state of the economy, have left many investors wary.

Read More